Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Management of Iron Deficiency Anaemia in Inflammatory Bowel Disease

Management of Iron Deficiency Anaemia in Inflammatory Bowel Disease Inflammatory bowel disease (IBD) is a group of chronic relapsing inflammatory disorders affecting the large and small intestine, with a rising worldwide incidence and prevalence. Anaemia is the most common extraintestinal manifestation of IBD, correlating with disease activity, and tending to relapse even after successful therapy. Iron deficiency is the most common cause; however, it often manifests in combination with anaemia of inflammation. As such, multiple parameters are used for the diagnosis of iron deficiency anaemia in IBD. Timely recognition and selection of appropriate therapy leads to an improvement in the quality of life and prevention of potential sequelae. Oral iron can be effective under specific circumstances; however, as luminal iron changes microbiota and bacterial metabolism, oral administration should be avoided. Intravenous iron is preferred as it bypasses the sites of inflammation. Nevertheless, the optimization of IBD treatment should occur simultaneously, as this improves both patient condition and response to iron therapy. Herein, we discuss the screening, diagnosis, selection of therapy, and follow-up for iron deficiency anaemia in IBD. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Haematologica Karger

Management of Iron Deficiency Anaemia in Inflammatory Bowel Disease

Download PDF
7 pages

Loading next page...
 
/lp/karger/management-of-iron-deficiency-anaemia-in-inflammatory-bowel-disease-gD9N5nesJn

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 2019 S. Karger AG, Basel
ISSN
0001-5792
eISSN
1421-9662
DOI
10.1159/000496728
Publisher site
See Article on Publisher Site

Abstract

Inflammatory bowel disease (IBD) is a group of chronic relapsing inflammatory disorders affecting the large and small intestine, with a rising worldwide incidence and prevalence. Anaemia is the most common extraintestinal manifestation of IBD, correlating with disease activity, and tending to relapse even after successful therapy. Iron deficiency is the most common cause; however, it often manifests in combination with anaemia of inflammation. As such, multiple parameters are used for the diagnosis of iron deficiency anaemia in IBD. Timely recognition and selection of appropriate therapy leads to an improvement in the quality of life and prevention of potential sequelae. Oral iron can be effective under specific circumstances; however, as luminal iron changes microbiota and bacterial metabolism, oral administration should be avoided. Intravenous iron is preferred as it bypasses the sites of inflammation. Nevertheless, the optimization of IBD treatment should occur simultaneously, as this improves both patient condition and response to iron therapy. Herein, we discuss the screening, diagnosis, selection of therapy, and follow-up for iron deficiency anaemia in IBD.

Journal

Acta Haematologica – Karger

Published: May 1, 2019

Keywords: Anaemia; Iron deficiency; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis

References

  • Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
    Ng, SC; Shi, HY; Hamidi, N; Underwood, FE; Tang, W; Benchimol, EI
  • Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis
    Filmann, N; Rey, J; Schneeweiss, S; Ardizzone, S; Bager, P; Bergamaschi, G
  • Anemia of chronic disorders: new diagnostic tools and new treatment strategies
    Weiss, G
  • Iron sensing and signalling
    Evstatiev, R; Gasche, C
  • Colitis O: european consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases
    Dignass, AU; Gasche, C; Bettenworth, D; Birgegard, G; Danese, S; Gisbert, JP
  • The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?
    Beutler, E; Waalen, J
  • The influence of high-altitude living on body iron
    Cook, JD; Boy, E; Flowers, C; Daroca, MC
  • Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease
    Oustamanolakis, P; Koutroubakis, IE; Messaritakis, I; Kefalogiannis, G; Niniraki, M; Kouroumalis, EA
  • Fergicor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev, R; Marteau, P; Iqbal, T; Khalif, IL; Stein, J; Bokemeyer, B; Chopey, IV; Gutzwiller, FS; Riopel, L; Gasche, C; Group, FS
  • Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement
    Gisbert, JP; Bermejo, F; Pajares, R; Pérez-Calle, JL; Rodríguez, M; Algaba, A
  • Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients
    Wells, CW; Lewis, S; Barton, JR; Corbett, S
  • Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls
    Bruner, AB; Joffe, A; Duggan, AK; Casella, JF; Brandt, J
  • Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study
    Wang, J; O’Reilly, B; Venkataraman, R; Mysliwiec, V; Mysliwiec, A
  • Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration
    Krayenbuehl, PA; Battegay, E; Breymann, C; Furrer, J; Schulthess, G
  • Prevalence of iron deficiency without anaemia in inflammatory bowel disease and impact on health-related quality of life
    González Alayón, C; Pedrajas Crespo, C; Marín Pedrosa, S; Benítez, JM; Iglesias Flores, E; Salgueiro Rodríguez, I
  • Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia
    Gasche, C; Waldhoer, T; Feichtenschlager, T; Male, C; Mayer, A; Mittermaier, C
  • Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD
    Lee, T; Clavel, T; Smirnov, K; Schmidt, A; Lagkouvardos, I; Walker, A
  • The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d’Ivoire
    Zimmermann, MB; Chassard, C; Rohner, F; N’goran, EK; Nindjin, C; Dostal, A
  • Oral iron exacerbates colitis and influences the intestinal microbiome
    Mahalhal, A; Williams, JM; Johnson, S; Ellaby, N; Duckworth, CA; Burkitt, MD
  • Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice
    Seril, DN; Liao, J; Ho, KL; Warsi, A; Yang, CS; Yang, GY
  • Tolerability of different oral iron supplements: a systematic review
    Cancelo-Hidalgo, MJ; Castelo-Branco, C; Palacios, S; Haya-Palazuelos, J; Ciria-Recasens, M; Manasanch, J
  • Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis
    Tolkien, Z; Stecher, L; Mander, AP; Pereira, DI; Powell, JJ
  • Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial
    Makrides, M; Crowther, CA; Gibson, RA; Gibson, RS; Skeaff, CM
  • Are we giving too much iron? Low-dose iron therapy is effective in octogenarians
    Rimon, E; Kagansky, N; Kagansky, M; Mechnick, L; Mashiah, T; Namir, M
  • Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women
    Moretti, D; Goede, JS; Zeder, C; Jiskra, M; Chatzinakou, V; Tjalsma, H
  • Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials
    Stoffel, NU; Cercamondi, CI; Brittenham, G; Zeder, C; Geurts-Moespot, AJ; Swinkels, DW
  • Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program
    Gasche, C; Ahmad, T; Tulassay, Z; Baumgart, DC; Bokemeyer, B; Büning, C
  • Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials
    Bonovas, S; Fiorino, G; Allocca, M; Lytras, T; Tsantes, A; Peyrin-Biroulet, L
  • Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis
    Stein, J; Haas, JS; Ong, SH; Borchert, K; Hardt, T; Lechat, E
  • Adverse reactions after intravenous iron infusion among inflammatory bowel disease patients in the united states, 2010-2014
    Akhuemonkhan, E; Parian, A; Carson, KA; Hutfless, S
  • Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
    Rampton, D; Folkersen, J; Fishbane, S; Hedenus, M; Howaldt, S; Locatelli, F
  • [Intravenous iron-dextran: therapeutic and experimental possibilities]
    Ganzoni, AM
  • A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial
    Kulnigg, S; Stoinov, S; Simanenkov, V; Dudar, LV; Karnafel, W; Garcia, LC
  • A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)
    Reinisch, W; Staun, M; Tandon, RK; Altorjay, I; Thillainayagam, AV; Gratzer, C
  • Diagnosis and management of iron deficiency anemia in patients with IBD
    Stein, J; Hartmann, F; Dignass, AU
  • Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment
    Kulnigg, S; Teischinger, L; Dejaco, C; Waldhör, T; Gasche, C
  • Red blood cell transfusion: a clinical practice guideline from the AABB*
    Carson, JL; Grossman, BJ; Kleinman, S; Tinmouth, AT; Marques, MB; Fung, MK
  • Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
    Evstatiev, R; Alexeeva, O; Bokemeyer, B; Chopey, I; Felder, M; Gudehus, M; Iqbal, T; Khalif, I; Marteau, P; Stein, J; Gasche, C; Group, FS
  • P294 iron-deficiency without anemia in crohn’s disease: what are the predictive factors of recovery?
    Cúrdia Gonçalves, T; Monteiro, S; Barbosa, M; Moreira, MJ; Cotter, J
  • Thrombocytosis in iron deficiency anemia
    Dan, K
  • Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial
    Kulnigg-Dabsch, S; Schmid, W; Howaldt, S; Stein, J; Mickisch, O; Waldhör, T
  • High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
    Simanek, R; Vormittag, R; Ay, C; Alguel, G; Dunkler, D; Schwarzinger, I
  • Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study
    Grainge, MJ; West, J; Card, TR
  • Tissue factor: a mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis
    Anthoni, C; Russell, J; Wood, KC; Stokes, KY; Vowinkel, T; Kirchhofer, D
  • Iron status, anemia, and plasma erythropoietin levels in acute and chronic mouse models of colitis
    Carter, PR; Watts, MN; Kosloski-Davidson, M; Prasai, K; Grisham, MB; Harris, NR
  • Role of intestinal hif-2alpha in health and disease
    Ramakrishnan, SK; Shah, YM
  • Increased expression of HIF2α during iron deficiency-associated megakaryocytic differentiation
    Jimenez, K; Khare, V; Evstatiev, R; Kulnigg-Dabsch, S; Jambrich, M; Strobl, H